224 related articles for article (PubMed ID: 19747113)
1. Multiplexed fluorescence imaging of tumor biomarkers in gene expression and protein levels for personalized and predictive medicine.
Smith MQ; Staley CA; Kooby DA; Styblo T; Wood WC; Yang L
Curr Mol Med; 2009 Nov; 9(8):1017-23. PubMed ID: 19747113
[TBL] [Abstract][Full Text] [Related]
2. Molecular beacon imaging of tumor marker gene expression in pancreatic cancer cells.
Yang L; Cao Z; Lin Y; Wood WC; Staley CA
Cancer Biol Ther; 2005 May; 4(5):561-70. PubMed ID: 15917666
[TBL] [Abstract][Full Text] [Related]
3. Personalized Circulating Tumor DNA Biomarkers Dynamically Predict Treatment Response and Survival In Gynecologic Cancers.
Pereira E; Camacho-Vanegas O; Anand S; Sebra R; Catalina Camacho S; Garnar-Wortzel L; Nair N; Moshier E; Wooten M; Uzilov A; Chen R; Prasad-Hayes M; Zakashansky K; Beddoe AM; Schadt E; Dottino P; Martignetti JA
PLoS One; 2015; 10(12):e0145754. PubMed ID: 26717006
[TBL] [Abstract][Full Text] [Related]
4. Molecular profiling of single cancer cells and clinical tissue specimens with semiconductor quantum dots.
Xing Y; Smith AM; Agrawal A; Ruan G; Nie S
Int J Nanomedicine; 2006; 1(4):473-81. PubMed ID: 17722280
[TBL] [Abstract][Full Text] [Related]
5. Personalized oncology: recent advances and future challenges.
Kalia M
Metabolism; 2013 Jan; 62 Suppl 1():S11-4. PubMed ID: 22999010
[TBL] [Abstract][Full Text] [Related]
6. Exploitation of Gene Expression and Cancer Biomarkers in Paving the Path to Era of Personalized Medicine.
Kamel HFM; Al-Amodi HSAB
Genomics Proteomics Bioinformatics; 2017 Aug; 15(4):220-235. PubMed ID: 28813639
[TBL] [Abstract][Full Text] [Related]
7. Novel secretome-to-transcriptome integrated or secreto-transcriptomic approach to reveal liquid biopsy biomarkers for predicting individualized prognosis of breast cancer patients.
Ankney JA; Xie L; Wrobel JA; Wang L; Chen X
BMC Med Genomics; 2019 May; 12(1):78. PubMed ID: 31146747
[TBL] [Abstract][Full Text] [Related]
8. HGF/MET pathway aberrations as diagnostic, prognostic, and predictive biomarkers in human cancers.
Moosavi F; Giovannetti E; Saso L; Firuzi O
Crit Rev Clin Lab Sci; 2019 Dec; 56(8):533-566. PubMed ID: 31512514
[TBL] [Abstract][Full Text] [Related]
9. Emerging evidence for CHFR as a cancer biomarker: from tumor biology to precision medicine.
Derks S; Cleven AH; Melotte V; Smits KM; Brandes JC; Azad N; van Criekinge W; de Bruïne AP; Herman JG; van Engeland M
Cancer Metastasis Rev; 2014 Mar; 33(1):161-71. PubMed ID: 24375389
[TBL] [Abstract][Full Text] [Related]
10. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
Rabjerg M
Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
[TBL] [Abstract][Full Text] [Related]
11. Nanotechnology: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2006; 6(19):1-43. PubMed ID: 23074489
[TBL] [Abstract][Full Text] [Related]
12. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
13. Prognostic and predictive biomarkers: tools in personalized oncology.
Nalejska E; Mączyńska E; Lewandowska MA
Mol Diagn Ther; 2014 Jun; 18(3):273-84. PubMed ID: 24385403
[TBL] [Abstract][Full Text] [Related]
14. Bioconjugated quantum dots for in vivo molecular and cellular imaging.
Smith AM; Duan H; Mohs AM; Nie S
Adv Drug Deliv Rev; 2008 Aug; 60(11):1226-1240. PubMed ID: 18495291
[TBL] [Abstract][Full Text] [Related]
15. In situ spectral imaging of marker proteins in gastric cancer with near-infrared and visible quantum dots probes.
He Y; Xu H; Chen C; Peng J; Tang H; Zhang Z; Li Y; Pang D
Talanta; 2011 Jul; 85(1):136-41. PubMed ID: 21645682
[TBL] [Abstract][Full Text] [Related]
16. Real-time detection of gene expression in cancer cells using molecular beacon imaging: new strategies for cancer research.
Peng XH; Cao ZH; Xia JT; Carlson GW; Lewis MM; Wood WC; Yang L
Cancer Res; 2005 Mar; 65(5):1909-17. PubMed ID: 15753390
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers for personalized oncology: recent advances and future challenges.
Kalia M
Metabolism; 2015 Mar; 64(3 Suppl 1):S16-21. PubMed ID: 25468140
[TBL] [Abstract][Full Text] [Related]
18. Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.
Beltran H; Eng K; Mosquera JM; Sigaras A; Romanel A; Rennert H; Kossai M; Pauli C; Faltas B; Fontugne J; Park K; Banfelder J; Prandi D; Madhukar N; Zhang T; Padilla J; Greco N; McNary TJ; Herrscher E; Wilkes D; MacDonald TY; Xue H; Vacic V; Emde AK; Oschwald D; Tan AY; Chen Z; Collins C; Gleave ME; Wang Y; Chakravarty D; Schiffman M; Kim R; Campagne F; Robinson BD; Nanus DM; Tagawa ST; Xiang JZ; Smogorzewska A; Demichelis F; Rickman DS; Sboner A; Elemento O; Rubin MA
JAMA Oncol; 2015 Jul; 1(4):466-74. PubMed ID: 26181256
[TBL] [Abstract][Full Text] [Related]
19. Status of Immune Oncology: Challenges and Opportunities.
Cesano A; Marincola FM; Thurin M
Methods Mol Biol; 2020; 2055():3-21. PubMed ID: 31502145
[TBL] [Abstract][Full Text] [Related]
20. Mass spectrometry-based proteomics: from cancer biology to protein biomarkers, drug targets, and clinical applications.
Jimenez CR; Verheul HM
Am Soc Clin Oncol Educ Book; 2014; ():e504-10. PubMed ID: 24857147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
